BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Dermatrends Announces Patent Related To Transdermal Delivery Of Broad Category Of Amine Drugs


10/19/2005 5:08:55 PM

MINNEAPOLIS, July 1 /PRNewswire/ -- Dermatrends, Inc., a drug delivery company, announced today that it has received a U.S. patent that covers the method of using bases to enhance the permeation of amine drugs across the skin. The patent is the eleventh granted to Dermatrends, all related to its breakthrough technology in the field of transdermal patch drug delivery. It covers the very wide drug category of amine drugs which includes a variety of compounds used to treat conditions ranging from Alzheimer's disease, to enlarged prostate, to acid reflux disease. To date, prescription drugs used in the treatment of these diseases have been available primarily in oral delivery format.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040701/CGTH053LOGO )

Dermatrends' new U.S. patent number 6,719,997 covers the use of hydroxide releasing agents with amine drugs. In its application, Dermatrends demonstrated that its base hydroxide-releasing agent was able to increase flux rates, or permeation. The newly issued patent adds to an intellectual property portfolio that includes a broad method patent for its enhancer system as well as numerous patents for its technology applied to large categories of drugs. These include peptides and non-steroidal anti-inflammatory drugs (NSAIDs). The company has also been issued patents for its technology applied to specific drug compounds.

Amine drugs are a very broad category of therapeutic drugs with approved compounds numbering literally in the thousands. Widely prescribed drugs in this category include donepezil and galantamine HBr, both used to treat Alzheimer's disease, and also the compounds tamsulosin, finasteride and dutasteride, all of which are used in the treatment of benign prostatic hyperplasia (BPH), commonly known as enlargement of the prostate. Another class of amine drugs includes proton pump inhibitors such as omeprazole, rabeprazole and lansoprazole, which are used to treat a form of acid reflux disease. Amine drugs also include compounds commonly used for pain relief, antidepressants, and amphetamines such as Ritalin(R), one of the drugs used to treat attention deficit hyperactive disorder (ADHD).

Dermatrends is currently working with pharmaceutical partners to bring its technology to consumers. Depending on the condition being treated, there are a number of potential consumer benefits to having the choice of a patch delivery alternative to an oral prescription. These benefits include improved patient compliance and minimization or elimination of side effects associated with oral delivery.

Dermatrends Chairman and Chief Executive Officer Ted Schwarzrock, said, "Dermatrends continues to break through existing barriers that have limited transdermal patch delivery to a very small number of compounds. The patent we are announcing today is another example of our ability to offer the pharmaceutical industry a new form of drug delivery technology that can open up a huge class of pharmacological compounds for transdermal delivery."

Dermatrends, Inc. is a privately held medical research and development company based in Minneapolis, Minn. with scientific laboratories in San Diego, Calif. The company is dedicated to the development of proprietary transdermal and other drug delivery technologies, and it has demonstrated an enabling platform technology that allows a broad variety of ethical and over-the- counter drugs to permeate the skin and mucosal surface and enter the bloodstream at therapeutic levels in excess of anything currently commercially available. The company is currently actively developing its partnerships and other relationships in the global pharmaceutical industry to commercially introduce its technology. Additional information is available on the company's website at http://www.dermatrends.com/ . For additional information, please email us at partnerships@dermatrends.com or call 612.843.2142.

Photo: http://www.newscom.com/cgi-bin/prnh/20040701/CGTH053LOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comDermatrends, Inc.

CONTACT: Joanne Henry for Dermatrends, +1-612-843-2142



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES